ImaValve (Intelligent materials for in-situ heart Valve tissue engineering) is a collaborative project funded by the European Commission under the Seventh European Framework Programme and brings together a unique consortium of academic and SMEsme partners from The Netherlands, Switzerland and Germany. The principal objective of the ImaValve project is to develop a new therapeutic strategy to treat heart valve disease patients more efficiently. In situ tissue engineering using a biodegradable synthetic scaffold that recruits endogenous cells from the bloodstream is emerging as a promising technology to create living heart valves inside the human body having the potential to last a life-time.: one valve for life. ImaValve aims to further develop the synthetic biomaterials needed for the in situ tissue engineering of heart valves, to process these materials into a functional heart valve scaffold, and to perform all the necessary pre-clinical experiments to enable first-in-man clinical application.